home / stock / cmvlf / cmvlf news

CMVLF News and Press, Cellectis Romainville Ord From 11/07/23

Stock Information
Company Name: Cellectis Romainville Ord
Stock Symbol: CMVLF
Market: OTC
Website: cellectis.com
Menu
CMVLF CMVLF Quote CMVLF Short CMVLF News CMVLF Articles CMVLF Message Board
Get CMVLF Alerts

News, Short Squeeze, Breakout and More Instantly...
CMVLF - Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript

2023-11-07 14:22:10 ET Cellectis SA (CLLS) Q3 2023 Earnings Conference Call November 07, 2023, 08:00 ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Co-founder, CEO& Director Mark Frattini - Chief Medical Officer Bing Wang -...
CMVLF - Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

•  Strategic Collaboration and Investment Agreements signed with AstraZeneca Updated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/r B-cell ALL and preliminary results of the Phase I NATHALI-01 Trial evaluating UCART20x22 in r/r B-cell NHL to be presented at ...

CMVLF - Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects

2023-11-03 18:57:50 ET Summary Preliminary data from two early-stage studies are going to be shown at the ASH 2023 conference, showcasing its cell therapy candidates for non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia. The company recently entered into a collaboration...

CMVLF - Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that preliminary res...
CMVLF - Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financi...

CMVLF - Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Collaboration leverages Cellectis’ gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate products Cellectis to receive up to $245M in cash (up to $220M equity investment and $25M upfront payment), with potential...

CMVLF - Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical da...
CMVLF - Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that they will be sh...

CMVLF - Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase ? Syndrome Type 1 (APDS1)

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new r...

CMVLF - Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data on...
Previous 10 Next 10